GEN webinar featuring Dr. Venkata Indurthi, Aldevron Chief Scientific Officer

Messenger RNA (mRNA) and self-amplifying RNA (saRNA) offer a unique opportunity for the development of novel therapeutics to treat a wide range of diseases. These modalities offer distinctive advantages over traditional therapies, from both biological and production standpoints. The success of RNA programs may depend heavily on the timeline to manufacture RNA molecules.

New ITR Cloning and Reporter Constructs Now Available

By Jeff Briganti, Senior Director, Global Strategic Marketing

Manufacturing standardization for cell and gene therapies (C&GT) has received increased focus in the last several years, spurred by the rapid exponential growth witnessed in this field. The resulting need for improved access to high-quality raw materials, including plasmid DNA, has made standardization integral to streamlining the development process for this biologic product category.

For recombinant adeno-associated virus (rAAV) viral vector production, we now offer several off-the-shelf ITR cloning backbones and GFP reporter constructs to complement our standardized set of OTS helper and packaging plasmids. This product set is available license and royalty free for research through commercial rAAV applications.

Utilizing this standardized portfolio can provide significant time and cost reduction, expediting time to market and de-risking specialized, transformative therapeutic development. By partnering with a contract development and manufacturing organization (CDMO) offering a complete suite of plasmids for viral vector production, researchers can streamline their upfront development while minimizing supply chain disruption throughout their program’s lifecycle.

For full information about our new product offering or to request a sample, visit our pALD-ITR Products page.

• Want to learn more about this topic? Contact Jeff Briganti with your questions
• Have an idea for a topic? Let us know!